Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 119

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 119
---
 Value                                            |     |   |  1,948,562 |   |
| Less:                                            
 Total Debt                                       |     |   | (1,239,646 | ) |
| Portion                                          
 of Enterprise Value Attributable to Shareholders |     | $ |    708,916 |   |
| Fair                                             
 Value per Shares                                 |     | $ |     0.0155 |   |

The abovementioned constitute the Company’s sole related party investment securities as of December 31, 2024.

5. ACCRUED EXPENSES

Accrued Expenses were comprised of the following:

|                  |     |   |        As 
        of 
  December 
  31, 2024 |     |   |        As 
        of 
 September 
  30, 2024 |
|:-----------------|:----|:--|----------:|:----|:--|----------:|
| Accrued          
 payroll taxes    |     | $ |     4,241 |     | $ |     4,241 |
| Accrued          
 Interest         |     |   |   387,885 |     |   |   362,533 |
| Accrued          
 Payroll          |     |   | 1,256,630 |     |   | 1,256,630 |
| Accrued          
 Rent             |     |   |    17,500 |     |   |         - |
| Other            
 Accrued Expenses |     |   |    41,423 |     |   |    41,423 |
| Total            |     | $ | 1,707,680 |     | $ | 1,664,827 |

<div align='center'>93</div>

6. UNEARNED INCOME

Unearned income is attributable to payments made to the Company and its wholly owned subsidiary pursuant to two license agreements for which income is recognized over the terms of the agreement.

7. NOTES PAYABLE

Notes Payable comprise of below:

(a) RELATED PARTY

Notes payable to related parties consisted of the following:

|                                  |     |   |          As 
 of December 
    31, 2024 |     |   |           As 
 of September 
      30,2024 |
|:---------------------------------|:----|:--|------------:|:----|:--|-------------:|
| David                            
 Koos                             |     |